At the news
? MIXEDIMPACT 7/10 8-K filed Aug 6, 2026 at 08:05 ET
Edgewise Therapeutics reported Q2 2026 net loss of $0.53/share, a 12.2% miss vs consensus of $-0.47, with no revenue. The quarter was dominated by the July 2026 completion of the sevasemten sale to Servier for $1.55B upfront (up to $2.65B total), transforming the balance sheet to a pro-forma $2.01B cash position and pivoting the company to a pure-play cardiovascular focus. Positive Phase 2 CIRRUS-HCM data for EDG-7500 supports a planned Phase 3 start in Q4 2026, but the company remains pre-revenue with widening operating losses as it funds the new pipeline.
- Net loss per share was $-0.53 for Q2 2026, compared to $-0.34 in Q2 2025, a 55.9% YoY increase in net loss.
- EPS of $-0.53 missed consensus of $-0.47 by 12.2%.
- Completed sale of sevasemten and muscular dystrophy business to Servier for $1.55B upfront cash (up to $2.65B total) in July 2026.
- Pro-forma cash balance post-sale is approximately $2.01B before taxes and transaction costs, up from $460.7M at quarter-end.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access